Jove
Visualize
Contact Us

Related Experiment Videos

Varicella-zoster virus. Prospects for active immunization.

A A Gershon

    American Journal of Clinical Pathology
    |July 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

    Epidemiology and infection·2016
    Same author

    Diagnostic virology.

    Pediatric clinics of North America·2015
    Same author

    Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to varicella-zoster virus.

    Clinical and vaccine immunology : CVI·2011
    Same author

    Population diversity in batches of the varicella Oka vaccine.

    Vaccine·2011
    Same author

    Evaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workers.

    Journal of virological methods·2011
    Same author

    Vaccination to prevent zoster in the elderly.

    Epidemiology and infection·2007
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    A live attenuated varicella-zoster virus vaccine effectively prevents chickenpox with minimal side effects. Antibody response is detected post-vaccination, persisting for at least two years.

    Area of Science:

    • Virology
    • Immunology
    • Vaccinology

    Background:

    • Varicella-zoster virus (VZV) causes chickenpox and shingles.
    • Development of effective VZV vaccines is crucial for public health.
    • Live attenuated vaccines offer a promising approach for VZV prevention.

    Purpose of the Study:

    • To evaluate the efficacy and safety of a live attenuated varicella-zoster virus vaccine.
    • To assess the immunogenicity and durability of the antibody response following vaccination.
    • To investigate the vaccine's potential to prevent VZV-related complications.

    Main Methods:

    • Development and testing of a live attenuated VZV vaccine by Dr. M. Takahashi and colleagues.
    • Administration of the VZV vaccine to a study cohort.

    Related Experiment Videos

  • Monitoring for VZV infection, adverse events, and antibody response using serologic techniques.

    • Main Results:

    • The VZV vaccine demonstrated apparent prevention of varicella.
    • Vaccination was associated with minimal side effects, even in high-risk individuals.
    • Antibody to VZV was detected post-vaccination and persisted for up to two years.

    Conclusions:

    • The live attenuated VZV vaccine is a promising candidate for preventing chickenpox.
    • The vaccine elicits a persistent antibody response.
    • Long-term studies are necessary to confirm the absence of VZV vaccine-associated zoster.